Venus Remedies

292.95
+0.95
(0.33%)
Market Cap
391.59 Cr
EPS
21.31
PE Ratio
14.01
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
427.90
52 Week low
270.25
PB Ratio
0.79
Debt to Equity
0.09
Add Ratio

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from1 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy100.00 %
100.00 %
Hold0.0 %
0.0 %
Sell0.0 %
0.0 %
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,664.05 3,99,261.34 33.68 49,887.20 12.06 9,648 13.77 47.46
5,507.25 1,46,200.18 71.18 8,184.00 0.89 1,600 64.53 40.99
1,450.10 1,17,112.11 23.41 26,520.70 14.17 4,155 47.38 48.78
3,074.40 1,04,051.67 55.61 10,785.70 11.59 1,656 13.54 47.28
1,093.95 91,280.38 17.35 28,905.40 12.36 5,578 1.69 31.30
2,169.15 89,491.95 44.67 10,615.60 19.57 1,942 -16.38 33.38
1,952.10 89,054.33 31.45 20,141.50 19.94 1,936 38.82 44.40
879.00 88,447.97 19.97 19,831.50 13.82 3,831 29.92 45.15
30,230.25 64,237.17 48.58 6,097.20 10.80 1,201 16.01 58.42
1,102.80 64,050.80 17.97 29,559.20 17.55 3,169 -10.04 42.48
Growth Rate
Revenue Growth
8.34 %
Net Income Growth
7.14 %
Cash Flow Change
-10.88 %
ROE
1.21 %
ROCE
11.31 %
EBITDA Margin (Avg.)
-6.60 %

Quarterly Financial Results

Quarterly Financials
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
68
92
77
95
75
89
99
84
191
146
128
135
132
205
126
145
145
142
121
159
97
171
146
199
110
178
189
Expenses
57
72
71
98
64
75
86
84
177
115
104
107
113
175
112
137
129
127
109
131
85
150
131
176
97
163
159
EBITDA
11
19
6
-3
11
14
13
0
13
31
24
29
19
30
14
8
16
15
12
28
13
21
14
23
13
16
30
Operating Profit %
15 %
18 %
6 %
-8 %
13 %
14 %
11 %
-2 %
6 %
8 %
15 %
4 %
13 %
13 %
10 %
4 %
10 %
9 %
7 %
16 %
11 %
11 %
8 %
10 %
10 %
3 %
10 %
Depreciation
9
9
9
9
9
9
9
7
9
9
9
9
9
9
9
8
8
9
7
8
8
6
7
6
6
6
5
Interest
8
11
10
0
6
5
4
-2
3
7
2
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Profit Before Tax
-6
-0
-12
-12
-4
1
0
-5
2
15
14
18
10
22
5
0
8
6
5
20
5
14
8
18
7
9
25
Tax
0
-1
-1
-0
0
0
1
1
0
2
2
-17
-2
-2
-1
0
1
0
1
9
4
4
1
7
6
6
5
Net Profit
-6
0
-12
-12
-4
0
-1
-5
2
13
12
35
12
23
6
0
7
5
3
11
1
10
7
11
1
4
20
EPS in ₹
-4.70
0.34
-9.50
-9.29
-3.30
0.34
-0.78
-4.38
1.60
10.55
9.44
28.45
8.86
17.32
4.22
0.17
5.16
3.99
2.46
8.27
0.88
7.44
5.13
7.86
0.92
2.63
14.66

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
841
843
765
751
733
644
556
580
601
627
Fixed Assets
444
453
406
389
364
289
262
241
216
219
Current Assets
233
277
259
260
265
294
234
278
323
360
Capital Work in Progress
78
80
66
65
65
25
25
25
26
21
Investments
0
0
0
0
0
0
0
0
20
19
Other Assets
319
310
293
297
304
330
269
314
339
368
Total Liabilities
841
843
765
751
733
644
556
580
601
627
Current Liabilities
163
193
197
230
264
225
97
93
83
79
Non Current Liabilities
222
212
180
159
137
96
58
47
58
60
Total Equity
457
438
389
362
333
323
400
440
460
488
Reserve & Surplus
445
426
376
350
320
311
374
427
447
474
Share Capital
11
11
12
12
12
12
12
13
13
13

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
Net Cash Flow
-1
4
-4
0
-1
-0
27
14
-22
Investing Activities
-67
3
-18
9
-11
-5
57
-17
-58
Operating Activities
68
47
59
31
45
78
132
41
37
Financing Activities
-1
-46
-44
-39
-35
-73
-162
-10
-1

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
35.89 %
40.81 %
40.81 %
40.81 %
40.81 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
1.03 %
1.59 %
1.48 %
1.06 %
1.18 %
1.11 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.15 %
0.15 %
0.15 %
0.15 %
0.15 %
0.15 %
0.15 %
0.15 %
0.15 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
54.71 %
51.21 %
51.95 %
52.18 %
51.72 %
49.97 %
50.18 %
50.04 %
49.24 %
48.66 %
48.20 %
47.25 %
46.89 %
46.25 %
45.31 %
45.42 %
Others
9.39 %
7.98 %
7.24 %
7.01 %
7.48 %
8.27 %
7.91 %
8.05 %
8.85 %
9.43 %
8.86 %
9.24 %
9.73 %
10.78 %
11.61 %
11.71 %
No of Share Holders
13,829
13,846
16,617
18,231
19,952
21,189
22,015
22,243
21,719
20,498
19,267
19,560
19,913
19,614
19,557
19,771

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Corporate Action

Announcements

Venus Remedies Secures Exclusive In-Licensing Rights From Infex Therapeutics To Develop And Commercialize MET-X In India
Feb 25, 2025, 10:08
Venus Remedies Secures Exclusive In-Licensing Rights From Infex Therapeutics To Develop And Commercialize MET-X In India
Feb 25, 2025, 10:08
Venus Remedies Gets Market Authorization For Anticoagulant Enoxaparin From Indonesia
Feb 10, 2025, 12:49
Announcement under Regulation 30 (LODR)-Newspaper Publication
Feb 06, 2025, 13:22
Integrated Filing (Financial)
Feb 05, 2025, 18:38
Intimation Under Regulation 30
Feb 04, 2025, 21:17
Unaudited Financial Results As On 31.12.2024
Feb 04, 2025, 21:03
Board Meeting Outcome for Outcome Of Board Meeting
Feb 04, 2025, 20:59
Board Meeting Intimation for Board Meeting Scheduled To Be Held On 04Th February 2025
Jan 24, 2025, 18:17
Venus Remedies Limited Successfully Renews EU GMP
Jan 20, 2025, 16:41
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Jan 07, 2025, 20:02
Venus Remedies Limited Expands Reach In Eastern European Market With Accreditation Of Good Manufacturing Practice (GMP ) Certification From Ministry Of Health Of Moldova
Dec 31, 2024, 13:08
Venus Remedies Secures Marketing Authorization In Philippines
Dec 06, 2024, 13:17
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Nov 29, 2024, 19:23
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Nov 05, 2024, 09:36
Announcement under Regulation 30 (LODR)-Newspaper Publication
Oct 30, 2024, 11:41
Financial Results As On 30.09.2024
Oct 29, 2024, 21:59
Board Meeting Outcome for Outcome Of Board Meeting Dated 29.10.24
Oct 29, 2024, 21:51
Board Meeting Intimation for Boar Meeting Is Scheduled For 29Th October 2024.
Oct 18, 2024, 14:28
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Oct 08, 2024, 17:13
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Oct 05, 2024, 15:24
Announcement under Regulation 30 (LODR)-Change in Management
Sep 30, 2024, 10:56
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Sep 24, 2024, 17:19
Closure of Trading Window
Sep 24, 2024, 14:30
Announcement under Regulation 30 (LODR)-Change in Management Control
Sep 23, 2024, 16:04
Proceedings Of 35Th Annual General Meeting Held On 23Rd September 2024.
Sep 23, 2024, 15:54
Announcement under Regulation 30 (LODR)-Newspaper Publication
Aug 24, 2024, 14:42
Reg. 34 (1) Annual Report.
Aug 21, 2024, 18:06
Reg. 34 (1) Annual Report.
Aug 21, 2024, 17:57
Notice Of 35Th Annual General Meeting And Cut-Of-Date/ E-Voting
Aug 21, 2024, 17:32
Book Closure Notice
Aug 21, 2024, 17:12
Announcement under Regulation 30 (LODR)-Newspaper Publication
Aug 16, 2024, 16:05
Announcement under Regulation 30 (LODR)-Newspaper Publication
Aug 14, 2024, 16:18
Announcement under Regulation 30 (LODR)-Change in Management
Aug 13, 2024, 19:40
Financial Results For The Quarter Ended 30Th June 2024.
Aug 13, 2024, 19:28
Board Meeting Outcome for Outcome Of Board Meeting Dated 13.08.2024
Aug 13, 2024, 19:25
Board Meeting Intimation for Notice Of Board Meeting To Be Held On 13Th August 2024.
Aug 01, 2024, 16:42
Cancellation of Board Meeting
Jul 17, 2024, 09:50
Successful Resolution Of Income Tax Case And Refund Of Rs. 21.27 Crores Received By Venus Remedies Limited
Jul 12, 2024, 14:14
Board Meeting Intimation for This Is To Inform You That The Meeting Of Board Of Directors Is Scheduled To Be Held On 20Th July 2024.
Jul 10, 2024, 12:02
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Jul 08, 2024, 17:46
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Jul 06, 2024, 12:27
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Jun 29, 2024, 11:15
Closure of Trading Window
Jun 26, 2024, 09:46
Venus Remedies Clinches WHO-Backed PAHO Tender, Takes Its Global Fight Against Cancer To Next Level
Jun 20, 2024, 14:06
Venus Remedies Achieves Major Milestone With UNICEF
Jun 13, 2024, 09:36
Announcement under Regulation 30 (LODR)-Newspaper Publication
Jun 01, 2024, 11:19
Financial Results As On 31.03.2024.
May 30, 2024, 20:54
Board Meeting Outcome for Outcome Of Board Meeting Dated 30.05.2024
May 30, 2024, 20:44
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
May 22, 2024, 11:02

Company Filings to Exchanges

Technical Indicators

RSI(14)
Neutral
42.99
ATR(14)
Less Volatile
14.66
STOCH(9,6)
Neutral
38.94
STOCH RSI(14)
Neutral
67.06
MACD(12,26)
Bearish
-1.40
ADX(14)
Weak Trend
9.63
UO(9)
Bearish
42.02
ROC(12)
Downtrend And Accelerating
-5.44
WillR(14)
Neutral
-70.05